In vivo, fraxinellone inhibits GBM tumor growth through inactivation of the SIRT3 signaling pathway, reinforcing SIRT3’s critical role in GBM tumorigenesis and its potential as a therapeutic target [91]. Here, SIRT3 is linked to glioblastoma.